Loading clinical trials...

Managed Access Programs for INC424, Ruxolitinib | Clinical Trials | Clareo Health

AVAILABLE

Managed Access Programs for INC424, Ruxolitinib

NCT04745637•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

Detailed Description

CINC424A2405 - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424A2405 to provide access to Ruxolitinib for patients with Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) CINC424A2001M - No longer available - Ruxolitinib Managed Access Program (MAP) for patients diagnosed with severe/very severe COVID-19 illness CINC424B2002I - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424B2002I to provide access to Ruxolitinib for patients with Polycythemia Vera (PV) CINC424C2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CINC424C2001M to provide access to ruxolitinib for steroid refractory acute and chronic Graft versus Host Disease (SR aGVHD and SR cGHVD).

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. An independent request was received from a licensed physician.
•2. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.

Exclusion Criteria

•4. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
•5. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
•6. Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
•7. Managed Access provision is allowed per local laws/regulations.

Key Dates

Last Updated

November 18, 2025

Conditions

Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Thrombocythemia Myelofibrosis (PET-MF)Severe/Very Severe COVID-19 IllnessPolycythemia Vera (PV)Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

Interventions

Ruxolitinib

DRUG

Contacts

MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs

CONTACT

1-88-669-6682 novartis.email@novartis.com

Novartis Pharmaceuticals

CONTACT

+41613241111

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727

Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions